Involvement of central μ-opioid system in the scratching behavior in mice, and the suppression of it by the activation of κ-opioid system

被引:105
作者
Umeuchi, H [1 ]
Togashi, Y [1 ]
Honda, T [1 ]
Nakao, K [1 ]
Okano, K [1 ]
Tanaka, T [1 ]
Nagase, H [1 ]
机构
[1] Toray Industries Ltd, Pharmaceut Res Labs, Kanagawa 2488555, Japan
关键词
pruritus; opioid system; TRK-820; CNS (central nervous system); behavior; (mouse);
D O I
10.1016/j.ejphar.2003.08.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The role of central mu- and kappa-opioid receptors in the regulation of itch sensation was examined using pruritogen-induced mouse scratching behavior model. Intracerebroventricular administration of beta-funaltrexamine, a selective mu-opioid receptor antagonist, inhibited the scratching behavior induced by intradermal substance P, but subcutaneous administration of beta-funaltrexamine did not. Similarly, the scratching inhibitory activity of subcutaneously administered TRK-820, (-)-17-(cyclopropylmethyl)-3, 14beta -dihydroxy-4, 5alpha-epoxy -6beta-[N-methyl-trans-3-(3-furyl) acrylamido] morphinan hydrochloride, a kappa-opioid receptor agonist, was antagonized by intracerebroventricular administration of nor-binaltorphimine (10 mug/site), a kappa-opioid receptor antagonist, but was not by subcutaneous administration of norbinaltorphimine. In addition, the scratching induced by the direct activation of central mu-opioid receptor by intracisternal morphine was significantly and dose-dependently inhibited by subcutaneous administration of TRK-820. Taken all together, it is suggested that the central mu-opioid receptors play a role in the processing of itch sensation, and the activation of central kappa-opioid receptors antagonize the central mu-opioid receptor mediated itch processing, thereby suppressing itch sensation. (C) 2003 Elsevier B.V. All rights reserved.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 45 条
[1]  
Andoh T, 1998, J PHARMACOL EXP THER, V286, P1140
[2]   ITCHING AFTER EPIDURAL AND SPINAL OPIATES [J].
BALLANTYNE, JC ;
LOACH, AB ;
CARR, DB .
PAIN, 1988, 33 (02) :149-160
[3]  
Barber A, 1997, Expert Opin Investig Drugs, V6, P1351, DOI 10.1517/13543784.6.10.1351
[4]   OPIATES, MAST-CELLS AND HISTAMINE-RELEASE [J].
BARKE, KE ;
HOUGH, LB .
LIFE SCIENCES, 1993, 53 (18) :1391-1399
[5]   Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: A controlled study [J].
Bergasa, NV ;
Alling, DW ;
Talbot, TL ;
Wells, MC ;
Jones, EA .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (03) :431-434
[6]   Open-label trial of oral nalmefene therapy for the pruritus of cholestasis [J].
Bergasa, NV ;
Schmitt, JM ;
Talbot, TL ;
Alling, DW ;
Swain, MG ;
Turner, ML ;
Jenkins, JB ;
Jones, EA .
HEPATOLOGY, 1998, 27 (03) :679-684
[7]  
COWAN A, 1997, P BRIT PHARM SOC M S, V122
[8]   Antipruritic and antihyperalgesic actions of loperamide and analogs [J].
DeHaven-Hudkins, DL ;
Cowan, A ;
Burgos, LC ;
Daubert, JD ;
Cassel, JA ;
DeHaven, RN ;
Kehner, GB ;
Kumar, V .
LIFE SCIENCES, 2002, 71 (23) :2787-2796
[9]   TREATMENT OF PRURITUS DUE TO CHRONIC OBSTRUCTIVE LIVER-DISEASE [J].
DUNCAN, JS ;
KENNEDY, HJ ;
TRIGER, DR .
BRITISH MEDICAL JOURNAL, 1984, 289 (6436) :22-22
[10]   Transnasal butorphanol for the treatment of opioid-induced pruritus unresponsive to antihistamines [J].
Dunteman, E ;
Karanikolas, M ;
Filos, KS .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1996, 12 (04) :255-260